Retrieved 23 September 2025
Theoretical and route-specific risks FDA's 2024 review specifically flagged that no published human exposure data exists for the subcutaneous, transdermal, or intranasal routes that compounding pharmacies have offered
Water, Centella Asiatica Leaf Water, Butylene Glycol, Glycerin, Dipropylene Glycol, Niacinamide, Hydroxyethyl Urea, Sodium Hyaluronate, Allantoin, Panthenol, Glutathione, Nelumbo Nucifera Extract, Artemisia Annua Extract, Oryza Sativa (Rice) Extract, Saccharomyces Ferment, Solanum Melongena (Eggplant) Fruit Extract, Melaleuca Alternifolia (Tea Tree) Leaf Extract, Hydrolyzed Collagen, Beta-Glucan, Hippophae Rhamnoides Fruit Extract, Adenosine, Madecassic Acid, Asiaticoside, Asiatic Acid, Squalane, Caprylic/Capric Triglyceride, Hydrogenated Lecithin, Glyceryl Stearate, Xanthan Gum, Propanediol, Hydroxyacetophenone, 1,2-Hexanediol, Ethylhexylglycerin, Dipotassium Glycyrrhizate, Citric Acid, Sodium Citrate
doi: 10.4161/cc.9.9.11358 76 BrubakerLYamamotoTJordanKMitraSBitlerB
Nanoencapsulation for drug delivery
Independently third-party tested for batch-to-batch consistency, certified 99% purity with lot-specific COAs